LOW MOLECULAR PROSTAGLAD INTRACTORS
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-11-02
- Publication Date
- 2026-03-04
AI Technical Summary
Current prostaglandin transporter (PGT) inhibitors are non-specific, leading to off-target effects, and there is a need for targeted and efficacious PGT inhibitors to manage conditions associated with prostaglandin levels, COX1 and COX2 activity, and to increase systemic levels of prostaglandin E2 and endogenous prostacyclin.
Development of a compound of Formula (1) and its pharmaceutically acceptable salts, which specifically inhibit PGT, thereby modulating prostaglandin signaling pathways and increasing PGE2 levels to treat conditions such as dysregulated hyperinflammation and pulmonary arterial hypertension.
The compound effectively inhibits PGT, providing targeted therapy for conditions like hyperinflammation and PAH, with reduced side effects and improved treatment efficacy.